| 1 |
34167562 | PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. | 2021 Jun 24 |
1 |
| 2 |
30956968 | Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib. | 2019 Mar |
1 |
| 3 |
28749919 | Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. | 2017 Jul |
1 |
| 4 |
29296813 | Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. | 2017 Sep 12 |
2 |
| 5 |
26298727 | Ruxolitinib induces autophagy in chronic myeloid leukemia cells. | 2016 Feb |
1 |
| 6 |
26459144 | Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib. | 2016 Jan |
1 |
| 7 |
25499760 | Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. | 2015 Feb 26 |
1 |
| 8 |
26430722 | Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. | 2015 Oct 2 |
1 |
| 9 |
24280282 | Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. | 2014 Feb |
1 |
| 10 |
25207766 | Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. | 2014 Sep 11 |
1 |